Investor Relations

Stock Data (click here)

SEC Filings (click here)

Press Releases (click here)

AIT Presentation (click here)

AIT Therapeutics Reports Second Quarter 2017 Financial Results Live webcast was online on Friday, August 11th, 2017 at 10:30am ET

AIT Therapeutics webcast for the Ladenburg Thalmann 2017 Healthcare Conference Live webcast was online Tuesday, September 26, 2017 at 4:00pm ET;
webcast will be archived for 365 days following the live presentation: http://wsw.com/webcast/ladenburg3/aitb/

AIT Therapeutics Reports Third Quarter 2017 Financial Results

AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30am ET

AIT Therapeutics to Present at Two Investor Conferences 30th Annual ROTH Conference – March 12, 2018 and Oppenheimer 28th Annual Healthcare Conference – March 20, 2018

AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast March 19, 2018

AIT Therapeutics Reports Year End 2017 Financial ResultsAIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference

AIT Therapeutics Presented Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex (MABSC) at the 2018 American Thoracic Society Conference

AIT Therapeutics Announces Change to Fiscal Year End and Financial Results Conference Call and Webcast for the Three Months Ended March 31, 2018

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast

AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences

AIT Therapeutics Announces $526,500 Sale of Common Stock To Institutional Investor, Lincoln Park Capital Fund

AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

 

For Investor Relations enquiry, please email IR[at]ait-pharm.com, for Business Development and other matters, email BD[at]ait-pharm.com